GABRA1
Gamma-aminobutyric acid receptor subunit alpha-1
As of the edition of 20 October 2026, GABRA1 (gamma-aminobutyric acid receptor subunit alpha-1, UniProt P14867) has 29 drugs tested at it and 65 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14867
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 85
- Disease areas
- Nervous system; Mental health; Cancer; Lungs and airways; Infections; Digestive system; Urinary and reproductive; Immune system
- Registered trials of its drugs
- 1,335
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 24 |
| Went quiet | 2 |
| Stopped | 3 |
| Total | 29 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Midazolam | Marketed | Phase 4 | none listed |
| Remimazolam | Marketed | Phase 4 | none listed |
| Zolpidem | Marketed | Phase 4 | none listed |
| Lorazepam | Marketed | Phase 4 | none listed |
| Alprazolam | Marketed | Phase 4 | none listed |
| Eszopiclone | Marketed | Phase 4 | none listed |
| Diazepam | Marketed | Phase 4 | none listed |
| Clonazepam | Marketed | Phase 4 | none listed |
| Flumazenil | Marketed | Phase 4 | none listed |
| Zopiclone | Marketed | Phase 4 | none listed |
| Clobazam | Marketed | Phase 4 | none listed |
| Padsevonil | Stopped | Phase 3 | none listed |
12 of 29 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 64 |
| Total on the list | 65 |
| Company | Route |
|---|---|
| Neurocrine | Route A |
The other 64 companies at GABRA1
In the product65 companies in all; 64 are not named here, and no score is.
See the 65 companies at GABRA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.